Company news
Kexing Biopharm Co., Ltd. news in 2025
Kexing Biopharm Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Renewing Engagement of Accounting Firm
December 15, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Ophthalmic Preparation GB10 Injection
December 8, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer Multiple
November 20, 2025
Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
November 17, 2025
Shareholders' Inquiry Transfer Plan
November 14, 2025
Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products
November 12, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 10, 2025
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
October 31, 2025
Report for Q3 2025
October 29, 2025
BioDlink Completes First International Shipment of Bevacizumab to Colombia
October 27, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 17, 2025
Announcement on Adjusting the Remuneration of Independent Directors
September 30, 2025
Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Registration Application for GB10 Injection
September 29, 2025
Announcement on Voluntary Disclosure of Inclusion of Human Interferon α1b Inhalation Solution Being Included in the List of Drugs Granted Breakthrough Therapy Designation
September 23, 2025
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
September 16, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase II Clinical Trial of GB08 for Injection
September 2, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
August 29, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 22, 2025
Announcement on Signing a Supplementary Agreement to Agreement of Related Party Transactions
August 15, 2025
BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
August 13, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
August 11, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 1% Integer Multiple
August 5, 2025
Announcement on General Election of Board of Directors
July 28, 2025
Announcement on Vesting Results and Share Listing in the 1st Vesting Period of the 2024 Restricted Stock Incentive Plan
July 10, 2025
Announcement on Shareholding Changes Reaching 1% Threshold, Completion of Shareholding Reduction Plan and Results of Shares Sold
July 9, 2025
Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm's Series of Globalization Activities in Shanghai
July 4, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 3, 2025
Announcement on the Progress of Proposed Transfer of Equity of Wholly-owned Subsidiary
July 2, 2025
Indicative Announcement on Change in Shareholder and Persons Acting in Concert's Equity Reaching an Integer Multiple of 5%
June 30, 2025
Kexing Biopharm's GB18 project received clearance of IND application from NMPA and FDA
May 28, 2025